MOUNTAIN VIEW, Calif., May 8, 2009 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will report financial results for the first quarter ended March 31, 2009 after the NASDAQ Market closes on Monday May 11, 2009. The company will conduct a conference call and an audio webcast at 2:00pm PT on the same day.
Date: May 11, 2009 Time: 2:00 PM PT
Listen via Internet: http://ir.vivus.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):http://apps.shareholder.com/PNWOutlook/t.aspx?m=37051&k=1FA26DDD
Toll-free: 877-545-1402 International: 719-325-4910
A webcast replay will be available on the VIVUS web site for 30 days.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(tm), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(tm), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(r) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.